Reaction
Hepatic Cancer Recurrent reporting signals
As of the last recalculation, Hepatic Cancer Recurrent appears in 281 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is LEDIPASVIR AND SOFOSBUVIR (PRR 206.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ledipasvir And Sofosbuvir | 45 | 206.2 | 206.7 |
| Sofosbuvir | 38 | 164.8 | 165.1 |
| Ribavirin | 41 | 55.1 | 55.2 |
| Regorafenib | 7 | 45.8 | 45.8 |
| Sorafenib | 10 | 36.9 | 37.0 |
| Velpatasvir And Sofosbuvir | 4 | 23.4 | 23.4 |
| Trifluridine And Tipiracil | 3 | 20.9 | 20.9 |